Related Experiment Video
Updated: May 20, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Monoclonal antibody dose determination and biodistribution into solid tumors
Robert A Beckman1, Reinhard von Roemeling, Andrew M Scott
1Oncology Clinical Research, Daiichi Sankyo Pharmaceutical Development, 399 Thornall Street, Edison, NJ 08837, USA. eniacl@snip.net
Abstract:
Monoclonal antibodies are increasingly being used as protein therapeutics for cancer. They offer very specific binding to target molecules on the surface of cancer cells, relatively few side effects and predictable pharmacokinetics. Tumor shrinkage is seen in some patients, and an incremental improvement in survival occurs in the group. However, due to their large size and consequent slow diffusion, antibody penetration deep into tumors may be inhomogeneous. Even if only a few cells, deep in tumors, escape therapy, they can regrow and lead to clinical relapse, limiting the significant potential of monoclonal antibody therapy. This leads to questions about optimal dosing for monoclonal antibodies. Methods to determine monoclonal antibody dose include maximum-tolerated dose studies, pharmacokinetically and pharmacodynamically guided dosing, randomized dose-ranging studies, imaging of antibody biodistribution and competitive-binding studies. Limitations of these methods, and future directions to possibly overcome these limitations will be discussed.
Insights
Monoclonal antibody cancer therapy shows promise but faces challenges with deep tumor penetration. Optimizing antibody dosing is crucial to overcome limitations and improve patient survival rates.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Monoclonal antibodies (mAbs) are effective cancer therapeutics with specific targeting and manageable side effects.
- While mAbs can induce tumor shrinkage and improve survival, their large size hinders deep tumor penetration, leading to potential therapeutic escape and relapse.
Purpose of the Study:
- To discuss the challenges of suboptimal dosing in monoclonal antibody cancer therapy.
- To review current methods for determining optimal monoclonal antibody dosage.
- To explore future directions for improving antibody dosing strategies.
Main Methods:
- Review of existing methods for monoclonal antibody dose determination.
- Analysis of limitations associated with current dosing strategies.
- Discussion of potential future research directions.
Main Results:
- Current dosing methods for monoclonal antibodies have limitations.
- Inhomogeneous antibody penetration in tumors can lead to treatment failure.
- Optimal dosing is critical for maximizing the efficacy of monoclonal antibody therapy.
Conclusions:
- Optimizing monoclonal antibody dosing is essential to overcome penetration challenges and improve cancer treatment outcomes.
- Further research into novel dosing strategies is needed to fully realize the potential of antibody therapeutics.
More Related Videos
Related Concept Videos
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies